APA (7th ed.) Citation

Felip, E., Mueller, C., Forster, M., Clay, T., Krebs, M., Horn, L., . . . Brignone, C. (2020). 790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC). BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Felip, Enriqueta, et al. 790 A Phase II Study (TACTI-002) of Eftilagimod Alpha (a Soluble LAG-3 Protein) with Pembrolizumab in PD-L1 Unselected Patients with Metastatic Non-small Cell Lung(NSCLC) or Head and Neck Carcinoma(HNSCC). BMJ Publishing Group, 2020.

MLA (8th ed.) Citation

Felip, Enriqueta, et al. 790 A Phase II Study (TACTI-002) of Eftilagimod Alpha (a Soluble LAG-3 Protein) with Pembrolizumab in PD-L1 Unselected Patients with Metastatic Non-small Cell Lung(NSCLC) or Head and Neck Carcinoma(HNSCC). BMJ Publishing Group, 2020.